Patents by Inventor Naisheng Bai

Naisheng Bai has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 9011936
    Abstract: Disclosed are methods of alleviating oxidative stress, regulating blood glucose levels, and controlling pancreatic lipase activity by administering a Rosemary extract. Such methods may be useful to help body weight and body fat, prevent obesity, and treat hyperglycemia, hyperinsulinemia, cardiovascular disease and Type-2 diabetes. Preferred extracts contain 20% or 50% carnosic acid.
    Type: Grant
    Filed: October 16, 2009
    Date of Patent: April 21, 2015
    Assignee: Naturex, S.A.
    Inventors: Kan He, Marc Roller, Alvin Ibarra, Naisheng Bai, Jacques DiKansky
  • Patent number: 8293292
    Abstract: A Fraxinus excelsior seed extract that can be administered for therapeutic treatment of a subject, including a human, by blocking fat synthesis, activating PPAR-alpha, increasing hypoglycemic activity, reducing bodyweight, controlling fasting plasma insulin levels against hyperinsulinemia, and promoting insulin sensitivity and causing a beneficial acute insulinotropic effect. The Fraxinus excelsior seed extract includes, inter alia, an isolated compound (2S,3E,4S)2H-Pyran-4-acetic acid-3-ethylidene-2-[(6-O-?-D-glucopyranosyl-?-D-glucopyranosyl)oxy]-3,4-dihydro-5-(methoxycarbonyl)methyl ester, commonly called excelside A, an isolated compound (2S,3E,4S) 2H-Pyran-4-acetic acid-3-ethylidene-2-[(6-O-?-D-glucopyranosyl-?-D-glucopyranosyl)oxy]-3,4-dihydro-5-(methoxycarbonyl)2-(4-hydroxyphenyl)ethyl ester, commonly called excelside B, and the compounds GI5, GI3, nuzhenide, and oleoside dimethyl ester.
    Type: Grant
    Filed: November 10, 2011
    Date of Patent: October 23, 2012
    Assignee: Naturex, S.A.
    Inventors: Kan He, Marc Roller, Antoine Bily, Naisheng Bai, Jacques DiKansky, Alvin Ibarra
  • Patent number: 8142826
    Abstract: A Fraxinus excelsior seed extract that can be administered for therapeutic treatment of a subject, including a human, by blocking fat synthesis, activating PPAR-alpha, increasing hypoglycemic activity, reducing bodyweight, controlling fasting plasma insulin levels against hyperinsulinemia, and promoting insulin sensitivity and causing a beneficial acute insulinotropic effect. The Fraxinus excelsior seed extract includes, inter alia, an isolated compound (2S,3E,4S) 2H-Pyran-4-acetic acid-3-ethylidene-2-[(6-O-?-D-glucopyranosyl-?-D-glucopyranosyl) oxy]-3,4-dihydro-5-(methoxycarbonyl)methyl ester, commonly called excelside A, an isolated compound (2S,3E,4S) 2H-Pyran-4-acetic acid-3-ethylidene-2-[(6-O-?-D-glucopyranosyl-?-D-glucopyranosyl)oxy]-3,4-dihydro-5-(methoxycarbonyl) 2-(4-hydroxyphenyl)ethyl ester, commonly called excelside B, and the compounds GI5, GI3, nuzhenide, and oleoside dimethyl ester.
    Type: Grant
    Filed: August 4, 2008
    Date of Patent: March 27, 2012
    Assignee: Naturex, Inc.
    Inventors: Kan He, Marc Roller, Antoine Bily, Naisheng Bai, Jacques Dikansky, Alvin Ibarra
  • Publication number: 20120058210
    Abstract: A Fraxinus excelsior seed extract that can be administered for therapeutic treatment of a subject, including a human, by blocking fat synthesis, activating PPAR-alpha, increasing hypoglycemic activity, reducing bodyweight, controlling fasting plasma insulin levels against hyperinsulinemia, and promoting insulin sensitivity and causing a beneficial acute insulinotropic effect. The Fraxinus excelsior seed extract includes, inter alia, an isolated compound (2S,3E,4S) 2H-Pyran-4-acetic acid-3-ethylidene-2-[(6-O-?-D-glucopyranosyl-?-D-glucopyranosyl)oxy]-3,4-dihydro-5-(methoxycarbonyl)methyl ester, commonly called excelside A, an isolated compound (2S,3E,4S) 2H-Pyran-4-acetic acid-3-ethylidene-2-[(6-O-?-D-glucopyranosyl-?-D-glucopyranosyl)oxy]-3,4-dihydro-5-(methoxycarbonyl) 2-(4-hydroxyphenyl)ethyl ester, commonly called excelside B, and the compounds GI5, GI3, nuzhenide, and oleoside dimethyl ester.
    Type: Application
    Filed: November 10, 2011
    Publication date: March 8, 2012
    Inventors: KAN HE, Marc ROLLER, Antoine BILY, Naisheng BAI, Jacques DIKANSKY, Alvin IBARRA
  • Publication number: 20110091580
    Abstract: Disclosed are methods of alleviating oxidative stress, regulating blood glucose levels, and controlling pancreatic lipase activity by administering a Rosemary extract. Such methods may be useful to help body weight and body fat, prevent obesity, and treat hyperglycemia, hyperinsulinemia, cardiovascular disease and Type-2 diabetes. Preferred extracts contain 20% or 50% carnosic acid.
    Type: Application
    Filed: October 16, 2009
    Publication date: April 21, 2011
    Inventors: KAN HE, Marc Roller, Alvin Ibarra, Naisheng Bai, Jacques Dikansky
  • Publication number: 20090117214
    Abstract: A Fraxinus excelsior seed extract that can be administered for therapeutic treatment of a subject, including a human, by blocking fat synthesis, activating PPAR-alpha, increasing hypoglycemic activity, reducing bodyweight, controlling fasting plasma insulin levels against hyperinsulinemia, and promoting insulin sensitivity and causing a beneficial acute insulinotropic effect. The Fraxinus excelsior seed extract includes, inter alia, an isolated compound (2S,3E,4S) 2H-Pyran-4-acetic acid-3-ethylidene-2-[(6-O-?-D-glucopyranosyl-?-D-glucopyranosyl) oxy]-3,4-dihydro-5-(methoxycarbonyl)methyl ester, commonly called excelside A, an isolated compound (2S,3E,4S) 2H-Pyran-4-acetic acid-3-ethylidene-2-[(6-O-?-D-glucopyranosyl-?-D-glucopyranosyl)oxy]-3,4-dihydro-5-(methoxycarbonyl) 2-(4-hydroxyphenyl)ethyl ester, commonly called excelside B, and the compounds G15, G13, nuzhenide, and oleoside dimethyl ester.
    Type: Application
    Filed: August 4, 2008
    Publication date: May 7, 2009
    Inventors: Kan He, Marc Roller, Antonie Bily, Naisheng Bai, Jacques Dikansky, Alvin Ibarra
  • Patent number: 7351739
    Abstract: In one aspect, the present invention provides compounds having formula I or IV as shown below: as further defined herein. In additional aspects, the present invention provides compositions and kits comprising the compounds of the invention and methods for their use, for example, for the prevention or treatment of a cancer.
    Type: Grant
    Filed: April 29, 2005
    Date of Patent: April 1, 2008
    Assignees: Wellgen, Inc., The Regents of the University of Minnesota, Rutgers, the State University of New Jersey
    Inventors: Chi-Tang Ho, Naisheng Bai, Zigang Dong, Ann M. Bode, Slavik Dushenkov
  • Publication number: 20070244190
    Abstract: Provided herein are methods of inducing apoptosis in cancer cells using neobritannilactone B (NAB) or acety neobritannilactone B (ANAB). Also provided are pharmaceutical compositions and methods for using NAB or ANAB to prevent or treat cancer in a mammal. Exemplary cancers include, for example, colon cancer, leukemia, and gastric cancer.
    Type: Application
    Filed: March 16, 2007
    Publication date: October 18, 2007
    Inventors: Chi-Tang Ho, Naisheng Bai, Min-Hsiung Pan
  • Publication number: 20060057228
    Abstract: The present invention provides a dietary supplement and methods of using the same to promote body weight reduction and/or loss of body fat in a subject, and for the management of obesity. The supplement can further be used to reduce one or more metabolic parameters in a subject, such as blood glucose levels, blood triglyceride levels, and blood cholesterol levels.
    Type: Application
    Filed: July 8, 2005
    Publication date: March 16, 2006
    Applicant: Pure World Botanicals, Inc.
    Inventors: Qun Zheng, Bo Zheng, Kan He, Bao Cui, Naisheng Bai
  • Publication number: 20060052438
    Abstract: In one aspect, the present invention provides compounds having formula I or IV as shown below: as further defined herein. In additional aspects, the present invention provides compositions and kits comprising the compounds of the invention and methods for their use, for example, for the prevention or treatment of a cancer.
    Type: Application
    Filed: April 29, 2005
    Publication date: March 9, 2006
    Inventors: Chi-Tang Ho, Naisheng Bai, Zigang Dong, Ann Bode, Slavik Dushenkov
  • Publication number: 20040052881
    Abstract: Compositions and methods for preventing and treating cancer are provided that comprise extracts of Inula britannica or compounds isolated therefrom.
    Type: Application
    Filed: September 15, 2003
    Publication date: March 18, 2004
    Inventors: Chi-Tang Ho, Mohammed Rafi, Robert S. DiPaola, Geetha Ghai, Robert T. Rosen, Naisheng Bai
  • Patent number: 6627623
    Abstract: Compositions and methods for preventing and treating cancer are provided that comprise extracts of Inula britannica or compounds isolated therefrom. The compounds of 1-O-acetylbritannilactone or 1,6-O,O-diacetylbritannilactone are isolated and used for inducing apoptosis in cells and for treating cancer in an animal. Induction of apoptosis comprises contacting cells with a composition comprising the compounds in an amount sufficient to induce Bcl-2 protein phosphorylation. Further, treatment of cancer in an animal comprises administering to an animal a composition comprising the compounds in an amount sufficient to induce Bcl-2 protein phosphorylation to treat the cancer.
    Type: Grant
    Filed: February 20, 2002
    Date of Patent: September 30, 2003
    Assignee: Rutgers, the State University
    Inventors: Chi-Tang Ho, Mohammed Rafi, Robert S. Dipaola, Geetha Ghai, Robert T. Rosen, Naisheng Bai
  • Publication number: 20020155178
    Abstract: Compositions and methods for preventing and treating cancer are provided that comprise extracts of Inula britannica or compounds isolated therefrom.
    Type: Application
    Filed: February 20, 2002
    Publication date: October 24, 2002
    Inventors: Chi-Tang Ho, Mohammed Rafi, Robert S. DiPaola, Geetha Ghai, Robert T. Rosen, Naisheng Bai